Invitation to First-Half 2026 webcast - Thursday 27 August 2026
2026-08-17 07:00:12
Oslo, Norway, 17 August 2026 - Oncoinvent ASA (ONCIN), a biotech company
developing a receptor-independent alpha radiopharmaceutical to eradicate cancer
cells in the abdominal cavity after surgery with a single, targeted dose, is
pleased to invite investors, analysts, and stakeholders to a live webcast event
at 10:00 a.m. CET on Thursday, 27 August 2026.
· Date: Thursday, 27 August 2026
· Time: 10:00 a.m. CET
· Webcast link: https://qcnl.tv/p/FlGvKEVec2WWcnTYYHBK4g
The First-Half 2026 Report and Presentation will be made available in the
Investors section of the Company's website at www.oncoinvent.com at 07:00 a.m.
CET. A recording of the webcast will be made available following the live
webcast.
Oncoinvent reports its financial results on a half-yearly basis, complemented by
quarterly business updates to keep stakeholders informed and ensure ongoing
transparency.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com
Optimum Strategic Communications
Zoe Bolt, Elena Bates, Katherine Bliss
+44 (0) 203 882 9621
oncoinvent@optimumcomms.com
About Oncoinvent
Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2026. With cost-effective manufacturing,
blockbuster potential, active pharma partnership momentum, plus strong
endorsements from leading experts, Oncoinvent is built for scale and commercial
success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by
Bayer).
care.\
The Company was founded by the originators of Algeta and Xofigo (acquired by\
Bayer).\